Ureteral Catheters Market in Denmark | Report – IndexBox

Executive Summary

Key Findings

• Procedure-driven demand with a high clinical dependency ratio: The Danish ureteral catheter market is fundamentally a procedure-driven segment, with demand directly correlated to the volume of urolithiasis interventions, ureteral obstruction cases, and uro-oncological surgeries. This dependency means that any shift in clinical guidelines toward selective stenting or changes in stone disease incidence directly impacts unit volumes, making procedure forecasting the most reliable demand proxy.
• Premium coating adoption is the primary value driver, not raw volume: In a high-income market like Denmark, the competitive battleground has shifted from basic catheter supply to advanced surface technologies. Hydrophilic, antimicrobial, and anti-encrustation coatings command significant price premiums and are increasingly specified in hospital tenders, meaning that value growth will outpace volume growth as the installed base of coated devices expands.
• Ambulatory Surgery Center (ASC) migration is restructuring procurement and service models: The progressive shift of ureteroscopy and stenting procedures from hospital operating rooms to ASCs and specialty urology clinics is altering buyer profiles, reducing per-case overhead, and increasing demand for pre-packed, procedure-ready kits. This migration demands that suppliers adapt their contracting, logistics, and service support models to smaller, more price-sensitive buyers with lower inventory buffers.
• Consolidated buyer groups create high switching costs and long qualification cycles: Danish hospital procurement is dominated by regional purchasing consortia and Integrated Delivery Networks (IDNs) that operate multi-year framework agreements. Winning a contract requires extensive clinical evidence, health-economic data, and regulatory documentation, creating significant barriers to entry for new suppliers and high switching costs for incumbent vendors.
• Supply chain resilience for medical-grade polymers and sterilization is a structural risk: The market is exposed to bottlenecks in specialty polymer resin supply (polyurethane, silicone copolymers) and sterilization capacity (ethylene oxide, gamma). Any disruption in these inputs can cause extended product shortages, as regulatory requalification for alternative materials or sterilization sites is a multi-month process under EU MDR and ISO 13485.
• EU MDR transition is compressing product portfolios and innovation cycles: The reclassification of ureteral catheters under EU MDR (Class IIa/IIb) has increased the cost and timeline for new product approvals and legacy device recertification. This regulatory burden is leading to portfolio rationalization by some suppliers, reducing the variety of niche catheter types available and slowing the introduction of next-generation biodegradable or drug-eluting stents.

Market Trends

The Danish ureteral catheter market is undergoing a structural transformation driven by clinical evidence, technological innovation, and care-setting evolution. The following trends are reshaping competitive dynamics and demand patterns through 2035.

• Rising adoption of antimicrobial and anti-encrustation coatings: With stent-related symptoms and infections representing a significant clinical and economic burden, coated catheters are becoming the standard of care in Danish hospitals. This trend is accelerating as health-economic evaluations demonstrate reduced complication rates and lower overall treatment costs, justifying the higher unit price.
• Growth of biodegradable and drug-eluting stent platforms: Early-stage clinical adoption of biodegradable ureteral stents, which eliminate the need for a second removal procedure, is gaining traction in academic medical centers. While currently limited to select cases, this technology has the potential to disrupt the replacement cycle and reduce procedural volumes for removal, shifting demand toward higher-value, single-insertion devices.
• Procedure kit bundling and value-based procurement: Danish hospital purchasing groups are increasingly moving away from unit-price bidding toward bundled procurement that includes catheters, guidewires, and access sheaths in a single procedure kit. This trend favors suppliers with broad product portfolios and integrated manufacturing capabilities, while disadvantaging single-product specialists.
• Expansion of ASC-based ureteroscopy and stenting: The decentralization of urological procedures from tertiary hospitals to ambulatory settings is accelerating, driven by clinical protocols for same-day discharge and cost-containment pressures. This shift requires catheters optimized for straightforward placement, shorter dwell times, and lower complication profiles, favoring standardized, easy-to-use designs.
• Increased demand for multilength and universal stents: To reduce inventory complexity and improve procedural efficiency, Danish hospitals are consolidating their stent inventories around multilength or universal designs that accommodate a range of ureteral lengths. This trend simplifies logistics but places greater demands on product design and physician training.

Strategic Implications

• Invest in clinical evidence generation for coating efficacy: Suppliers must prioritize health-economic studies and randomized controlled trials demonstrating the cost-effectiveness of coated catheters in reducing stent-related symptoms, infections, and encrustation. This evidence is critical for winning framework agreements with Danish IDNs and justifying premium pricing.
• Develop ASC-specific packaging and logistics solutions: The migration to ambulatory settings demands procedure-ready kits, smaller pack sizes, and just-in-time delivery models. Suppliers should design packaging for aseptic presentation in smaller procedure rooms and offer consignment inventory models to reduce ASC capital outlay.
• Build regulatory capacity for EU MDR compliance: The cost and complexity of maintaining CE marking under EU MDR will continue to rise. Companies should invest in dedicated regulatory teams, conduct gap analyses for legacy products, and prioritize portfolio investments in devices with clear clinical differentiation to justify recertification costs.
• Secure alternative sterilization and polymer supply chains: To mitigate supply bottlenecks, suppliers should dual-source medical-grade polymers, qualify multiple sterilization facilities (both EO and gamma), and maintain strategic buffer inventories. This resilience will become a competitive differentiator in tender evaluations.
• Target IDN and regional consortia with integrated contracting: Rather than pursuing individual hospital accounts, suppliers should develop multi-year, multi-product agreements with Danish regional health authorities. These contracts should include volume commitments, clinical support services, and training programs to create deep switching costs.

Key Risks and Watchpoints

• EU MDR transition delays and portfolio rationalization: The reclassification of ureteral catheters under EU MDR may lead to the withdrawal of lower-volume, niche products from the Danish market, reducing clinical options for complex cases and creating gaps in hospital formularies.
• Sterilization capacity constraints and lead-time volatility: Increasing demand for ethylene oxide sterilization across all medical devices, combined with regulatory pressures on EO emissions, could extend lead times to 12–16 weeks, disrupting hospital inventory planning and procedure scheduling.
• Shifts in clinical guidelines toward routine stenting avoidance: Growing evidence supporting selective stenting after uncomplicated ureteroscopy could reduce the number of stents placed per procedure, directly contracting market volume growth even as procedure volumes rise.
• Price erosion in standard, uncoated catheter segments: As coated catheters become the premium standard, basic double-J stents may face commoditization and aggressive price competition from low-cost manufacturers, compressing margins in the entry-level segment.
• Physician preference variability and training requirements: The introduction of new catheter designs, particularly biodegradable or multilength stents, requires significant physician training and adoption support. Inadequate training can lead to poor clinical outcomes, product returns, and loss of hospital accreditation.
• Budgetary pressure on Danish healthcare spending: Macroeconomic constraints on regional health budgets could lead to delayed procurement cycles, increased use of lower-cost alternatives, or extended reuse of single-use devices, all of which would suppress market value growth.

Market Scope and Definition

This report defines the Denmark ureteral catheters market as encompassing sterile, single-use or reusable tubular devices inserted into the ureter for the purpose of draining urine from the kidney to the bladder, providing access for diagnostic or therapeutic procedures, or maintaining ureteral patency. The product category includes Double-J/Pigtail stents, open-ended ureteral catheters, ureteral occlusion catheters, nephroureteral stents, multilength/universal stents, and devices with specialty coatings including hydrophilic, lubricious, antimicrobial, and anti-encrustation technologies. The scope covers devices used across hospital operating rooms, cystoscopy suites, ambulatory surgery centers (ASCs), specialty urology clinics, and academic medical centers in Denmark. Key applications include urolithiasis management, ureteral obstruction relief, post-ureteroscopy stenting, uro-oncological procedures (prostate, cervical, colorectal cancers), ureteral trauma and leak management, and renal transplant surgery. The market is segmented by device type, coating technology, and end-use setting, with analysis spanning pre-operative planning, intra-operative placement, post-operative management, follow-up removal or exchange, and complication management.

Explicitly excluded from this market scope are urethral catheters, suprapubic catheters, nephrostomy tubes without a ureteral segment, ureteral access sheaths, ureteral dilators, and non-urological stents (biliary, vascular). Adjacent products that are excluded but clinically related include ureteral stone retrieval devices (baskets), ureteral balloons, guidewires, endoscopes (cystoscopes, ureteroscopes), lithotripters, and contrast agents. These exclusions are critical for maintaining analytical focus on the ureteral catheter as a distinct device category with its own regulatory pathway, clinical workflow, and procurement dynamics. The report does not cover capital equipment such as fluoroscopy systems or ureteroscopes, nor does it address the disposable accessories used in conjunction with catheter placement, except where they are bundled into procedure kits that include catheters. The analysis is anchored in the device-level economics, clinical utilization patterns, and supply-chain characteristics specific to ureteral catheters in the Danish healthcare system.

Clinical, Diagnostic and Care-Setting Demand

Demand for ureteral catheters in Denmark is fundamentally driven by procedure volumes across three primary clinical indications: urolithiasis (stone disease), malignant ureteral obstruction from pelvic cancers, and benign ureteral strictures or trauma. Urolithiasis represents the largest volume driver, with ureteroscopy and laser lithotripsy being the dominant treatment modality, followed by routine placement of double-J stents for post-operative drainage. The prevalence of stone disease in Denmark is consistent with other high-income Nordic countries, with age-standardized incidence rates rising due to dietary factors, obesity, and an aging population. Malignant ureteral obstruction, secondary to prostate, cervical, and colorectal cancers, is a growing demand driver as cancer survival rates improve and patients live longer with advanced disease requiring palliative ureteral stenting. Renal transplant surgery, while lower in volume, represents a high-acuity, recurring demand for specialized nephroureteral stents with specific length and coating requirements. The clinical workflow for catheter placement is predominantly cystoscopic or fluoroscopic, with the majority of procedures performed in hospital operating rooms or dedicated cystoscopy suites, though a growing share is migrating to ASCs and outpatient clinic settings.

The demand structure is characterized by a mix of routine and complex cases, with replacement cycles varying by device type and patient condition. Standard double-J stents for post-ureteroscopy drainage typically have a dwell time of 1–4 weeks, while stents for malignant obstruction may remain in situ for 3–6 months or longer, requiring periodic exchange. This creates a recurring, predictable demand stream for exchange procedures, which account for a significant portion of total catheter utilization. Buyer types include hospital procurement departments operating under regional framework agreements, ASC group purchasing organizations, urology practice administrators, and IDN sourcing teams. The procurement decision is heavily influenced by physician preference, clinical evidence for coating efficacy, and total cost of care, including complication rates and removal costs. Utilization intensity is higher in academic medical centers and tertiary referral hospitals that manage complex stone cases and malignant obstructions, while ASCs and community hospitals predominantly use standardized, short-dwell catheters for uncomplicated procedures. The installed base of cystoscopic and fluoroscopic equipment in Danish hospitals supports a stable procedural environment, with replacement cycles for capital equipment influencing the adoption of new catheter technologies that require specific imaging or placement techniques.

Supply, Manufacturing and Quality-System Logic

The manufacturing of ureteral catheters is a precision engineering process that demands expertise in medical-grade polymer extrusion, tip forming, and coating application. The primary raw materials are medical-grade polyurethane, silicone, and copolymer blends, each selected for biocompatibility, flexibility, and resistance to encrustation. Specialty coating materials, including hydrophilic polymers for lubricity, silver-based or antibiotic-eluting compounds for antimicrobial activity, and phosphorylcholine or heparin-based coatings for anti-encrustation, are applied through dip-coating, spray-coating, or plasma deposition processes. Radiopaque markers, typically incorporating barium sulfate or bismuth compounds, are embedded in the catheter body or tip to enable fluoroscopic visualization during placement. The manufacturing process requires strict environmental controls, cleanroom conditions (ISO Class 7 or better), and validated sterilization methods, primarily ethylene oxide (EO) or gamma irradiation. Quality systems must comply with ISO 13485, with additional biocompatibility testing per ISO 10993 for cytotoxicity, sensitization, irritation, and systemic toxicity. Each production lot requires sterility testing, pyrogen testing, and functional testing for tensile strength, flow rate, and balloon integrity (where applicable).

Critical supply bottlenecks in the Danish market context include the security of medical-grade polymer resin supply, which is concentrated among a few global chemical suppliers, and the availability of specialty coating raw materials, which often have long lead times and limited secondary sourcing options. Sterilization capacity is a structural constraint, with EO sterilization facilities facing regulatory pressure to reduce emissions and gamma irradiation capacity constrained by cobalt-60 supply and facility maintenance schedules. Lead times for sterilization can extend to 8–12 weeks, requiring manufacturers to maintain significant finished goods inventory. Regulatory requalification for process changes, such as switching polymer suppliers or sterilization sites, is a multi-month process under EU MDR and ISO 13485, creating high switching costs and supply chain rigidity. Skilled labor for precision extrusion and coating application is a specialized resource, with a limited talent pool in Denmark and the broader Nordic region, leading to reliance on contract manufacturing organizations (CMOs) in other European hubs. The manufacturing logic favors vertically integrated producers who control extrusion, coating, and sterilization in-house, as this reduces qualification complexity and improves supply chain reliability, though it requires significant capital investment in cleanroom infrastructure and validation equipment.

Pricing, Procurement and Service Model

Pricing in the Danish ureteral catheter market is structured across multiple layers, reflecting the complexity of procurement pathways and the diversity of buyer types. List prices per unit vary significantly based on device features: basic, uncoated double-J stents are priced at the lowest tier, while hydrophilic-coated stents command a moderate premium, and antimicrobial or anti-encrustation coated devices achieve the highest price points. Multilength and universal stents, which reduce inventory SKU count, are typically priced at a premium to standard fixed-length devices. Contract pricing with GPOs and IDNs is negotiated on a volume-tiered basis, with larger annual commitments securing discounts of 15–30% off list price. Procedure kit bundling, where the catheter is packaged with guidewires, access sheaths, and sometimes a drainage bag, creates a blended pricing structure that can obscure individual device costs but simplifies hospital procurement and reduces per-procedure transaction costs. Distributor margins in Denmark typically range from 10–20%, depending on the level of service support provided, including inventory management, consignment stock, and clinical training. Service and consignment model pricing is emerging, particularly for ASCs, where the supplier retains ownership of the inventory until the point of use, reducing the buyer’s capital outlay and inventory risk.

Procurement in Denmark is dominated by regional health authority framework agreements, which set standardized pricing and terms for all public hospitals within a region. These agreements are typically awarded for 2–4 years, with rigorous evaluation criteria including clinical evidence, total cost of ownership, supply reliability, and sustainability credentials. Switching costs are high, as changing catheter suppliers requires physician retraining, new clinical protocols, and requalification of sterilization and packaging processes. The procurement decision is increasingly influenced by health-economic analyses that model the total cost of care, including complication rates, removal costs, and patient outcomes, rather than unit price alone. For ASCs and private urology clinics, procurement is more flexible but price-sensitive, with a preference for standardized, easy-to-use devices that minimize training requirements and inventory complexity. Tender processes for public hospitals require extensive documentation, including ISO 13485 certification, CE marking under EU MDR, biocompatibility data, and sterilization validation reports. The service model includes clinical training for physicians and nursing staff, technical support for device placement, and post-market surveillance reporting, all of which are factored into the total cost of procurement. Maintenance and training burdens are relatively low for disposable catheters compared to capital equipment, but the qualification process for new products remains a significant barrier to entry.

Competitive and Channel Landscape

The competitive landscape in the Danish ureteral catheter market is shaped by a mix of global full-portfolio urology device companies, specialized stent-focused innovators, and OEM/contract manufacturing specialists. Global full-portfolio players dominate the market due to their broad product ranges, established distribution networks, and deep relationships with hospital procurement departments and IDNs. These companies offer complete procedure solutions, including catheters, guidewires, access sheaths, and sometimes endoscopic equipment, enabling them to negotiate bundled contracts and create switching costs through integrated product ecosystems. Specialized stent-focused innovators compete on technology differentiation, particularly in advanced coatings, biodegradable materials, and drug-eluting platforms. These companies often target academic medical centers and early-adopter hospitals, leveraging clinical publications and physician champions to gain market share. OEM and contract manufacturing specialists serve as supply partners for larger companies, providing precision extrusion, coating application, and sterilization services, but have limited direct market access in Denmark. The competitive dynamics are characterized by moderate concentration, with the top three to five players accounting for the majority of market share, but with room for niche players to capture segments such as pediatric catheters or oncology-specific stents.

Channel access in Denmark is primarily through direct sales forces for the largest global players, who maintain dedicated urology sales teams with clinical specialists who support procedures and build physician relationships. Regional distributors and specialty urology device distributors serve as intermediaries for smaller companies, providing local inventory, logistics, and customer service. The distributor network in Denmark is relatively consolidated, with a few key players covering the entire country, making distributor selection a critical strategic decision. Hospital access is gated by procurement frameworks, with new suppliers required to undergo a formal qualification process that includes product evaluation, clinical trials, and health-economic assessment. Physician preference remains a powerful force, with key opinion leaders at academic medical centers influencing product selection across regional networks. The competitive advantage increasingly lies in the ability to provide clinical evidence, training support, and supply chain reliability rather than in product features alone. The channel landscape is evolving with the growth of ASCs, which require different service models, including smaller pack sizes, just-in-time delivery, and consignment inventory, favoring suppliers with flexible logistics capabilities. Integrated delivery networks are consolidating purchasing power, pushing suppliers toward multi-year, multi-product agreements that reward scale and breadth of portfolio.

Geographic and Country-Role Mapping

Denmark functions as a high-income, innovation-adopting market within the broader European and Nordic urology device landscape. The country’s healthcare system is characterized by universal coverage, centralized procurement through five regional health authorities, and a strong emphasis on evidence-based medicine and health technology assessment. As a high-income market, Denmark exhibits a high adoption rate of premium coated and specialty ureteral catheters, with clinicians and procurement bodies willing to pay a premium for devices that demonstrate reduced complication rates and improved patient outcomes. The domestic demand intensity is moderate relative to larger European markets, but the per-capita utilization of ureteral catheters is among the highest in the Nordic region, driven by high stone disease prevalence and a well-developed urology service infrastructure. Denmark serves primarily as a consumption market rather than a manufacturing or export hub for ureteral catheters, with the majority of devices imported from global manufacturing sites in Europe, the United States, and Asia. The country’s role in the value chain is as a reference market for clinical evidence generation and health-economic modeling, with Danish clinical studies often cited in regulatory submissions and procurement evaluations across other European markets.

The geographic mapping reveals a concentration of urology procedure volume in the major urban centers of Copenhagen, Aarhus, Odense, and Aalborg, where tertiary referral hospitals and academic medical centers manage complex stone cases and malignant obstructions. Regional hospitals in smaller cities perform a higher proportion of routine, uncomplicated procedures, driving demand for standardized, easy-to-use catheters. The installed base of endoscopic and fluoroscopic equipment is well-distributed across the country, supporting consistent procedural access. Denmark’s proximity to other Nordic markets (Sweden, Norway, Finland) creates opportunities for regional distribution hubs and cross-border clinical collaboration, though each country maintains independent procurement frameworks. The country’s role as an innovation hub is limited, with no major domestic manufacturing of ureteral catheters, but Danish academic institutions are active in clinical research on stent coatings and biodegradable materials. The import dependence of the Danish market creates exposure to global supply chain disruptions, currency fluctuations, and regulatory changes in manufacturing countries. For suppliers, Denmark represents a high-value, reference market where clinical adoption can influence broader European acceptance, but where procurement complexity and regulatory demands require dedicated local resources and market access capabilities.

Regulatory and Compliance Context

The regulatory framework governing ureteral catheters in Denmark is defined by the European Union Medical Device Regulation (EU MDR 2017/745), which classifies these devices as Class IIa or IIb depending on their intended use, duration of contact, and risk profile. Standard double-J stents for short-term drainage are typically Class IIa, while devices with antimicrobial coatings, drug-eluting properties, or extended dwell times may be classified as Class IIb, requiring more rigorous clinical evaluation and notified body oversight. All devices must bear CE marking, demonstrating conformity with the regulation’s general safety and performance requirements (GSPRs), and must be registered with the Danish Medicines Agency (Lægemiddelstyrelsen) for market surveillance purposes. The transition from the Medical Device Directive (MDD) to EU MDR has significantly increased the regulatory burden, requiring manufacturers to submit detailed technical documentation, clinical evaluation reports (CERs), post-market surveillance plans (PMS plans), and periodic safety update reports (PSURs). Notified bodies designated under EU MDR have limited capacity, leading to extended review timelines of 12–18 months for new device certifications and 18–24 months for legacy device recertification. This has created a bottleneck in product approvals and is driving portfolio rationalization, with some manufacturers discontinuing lower-volume products rather than bearing the cost of recertification.

Quality system compliance with ISO 13485 is mandatory for all manufacturers, with additional requirements for sterilization validation per ISO 11135 (ethylene oxide) or ISO 11137 (gamma irradiation), and biocompatibility testing per ISO 10993 series. The Danish healthcare system also imposes specific requirements for traceability, with hospitals requiring unique device identification (UDI) for inventory management and adverse event reporting. Post-market surveillance is a critical regulatory obligation, requiring manufacturers to actively monitor device performance in the Danish market, report serious incidents to the competent authority within specified timelines, and conduct field safety corrective actions (FSCAs) when necessary. The regulatory context is further complicated by country-specific import licenses and customs documentation for devices manufactured outside the EU, which can add 4–8 weeks to lead times. For suppliers entering the Danish market, the regulatory pathway requires a substantial investment in technical documentation, clinical evidence generation, and quality system implementation, with total costs for a new Class IIb device certification estimated at EUR 200,000–500,000 and timelines of 2–3 years. The regulatory burden creates a significant barrier to entry for smaller companies and favors established players with dedicated regulatory affairs teams and existing CE marking for related products. Compliance with the EU Medical Device Regulation is not static; manufacturers must continuously update their technical documentation in response to new scientific evidence, clinical data, and regulatory guidance, creating an ongoing operational cost.

Outlook to 2035

The Denmark ureteral catheter market is projected to experience moderate volume growth through 2035, driven by demographic trends, rising stone disease prevalence, and expanding indications for ureteral stenting in oncology and transplant surgery. The aging Danish population, with a growing proportion of individuals over 65, will increase the incidence of urolithiasis, benign prostatic hyperplasia causing obstruction, and pelvic cancers requiring palliative stenting. Volume growth will be partially offset by clinical shifts toward selective stenting after uncomplicated ureteroscopy, as guidelines increasingly recommend avoiding routine stent placement in low-risk patients. The value growth trajectory will be more robust than volume growth, driven by the continued adoption of premium coated catheters, multilength universal stents, and emerging biodegradable platforms that command higher unit prices. The migration of procedures from hospital operating rooms to ASCs and outpatient clinics will accelerate, potentially accounting for 30–40% of ureteral catheter placements by 2035, reshaping procurement models and service requirements. Technology shifts toward biodegradable stents, which eliminate the need for removal procedures, could reduce total procedure volumes but increase per-device value, creating a net positive impact on market revenue if adoption reaches critical mass.

Scenario drivers for the outlook include the pace of EU MDR implementation and its impact on product availability, the evolution of Danish health technology assessment (HTA) criteria for premium devices, and macroeconomic pressures on regional health budgets. In a base-case scenario, steady adoption of coated catheters and gradual expansion of ASC-based procedures will support 3–5% annual value growth through 2035. In an upside scenario, rapid acceptance of biodegradable stents and drug-eluting platforms, combined with favorable HTA recommendations, could drive 6–8% annual value growth. In a downside scenario, prolonged EU MDR transition delays, budget austerity, and clinical guideline shifts toward stenting avoidance could suppress growth to 1–2% annually. Replacement cycles for standard double-J stents will remain short (1–4 weeks), while specialty stents for malignant obstruction will sustain longer dwell times (3–6 months), creating a stable recurring demand base. The quality burden will intensify, with manufacturers required to invest in real-world evidence generation, digital traceability systems, and enhanced post-market surveillance capabilities. Adoption pathways for new technologies will be gated by clinical evidence requirements, with Danish hospitals demanding randomized controlled trials or large registry studies before approving formulary additions. The market will remain attractive for suppliers with differentiated coating technologies, robust regulatory capabilities, and flexible service models adapted to the ASC environment.

Strategic Implications for Manufacturers, Distributors, Service Partners and Investors

The Denmark ureteral catheter market presents a mature, high-value opportunity that rewards clinical evidence generation, regulatory execution, and service density over pure volume-based strategies. For manufacturers, the primary strategic imperative is to invest in differentiated coating technologies and biodegradable platforms that justify premium pricing and create barriers to commoditization. Companies should prioritize obtaining CE marking under EU MDR for a focused portfolio of high-value devices rather than attempting to maintain a broad, undifferentiated product range. The development of procedure-ready kits that bundle catheters with complementary disposables will be essential for winning bundled contracts with Danish IDNs and regional health authorities. Manufacturers must also build dedicated regulatory affairs capabilities for the Danish market, including expertise in HTA submissions and post-market surveillance reporting,